High Antibody Titer Against Apical Membrane Antigen-1 is Required to Protect Against Malaria in the Aotus Model
Overview
Authors
Affiliations
A Plasmodium falciparum 3D7 strain Apical Membrane Antigen-1 (AMA1) vaccine, formulated with AS02(A) adjuvant, slowed parasite growth in a recent Phase 1/2a trial, however sterile protection was not observed. We tested this AS02(A), and a Montanide ISA720 (ISA) formulation of 3D7 AMA1 in Aotus monkeys. The 3D7 parasite does not invade Aotus erythrocytes, hence two heterologous strains, FCH/4 and FVO, were used for challenge, FCH/4 AMA1 being more homologous to 3D7 than FVO AMA1. Following three vaccinations, the monkeys were challenged with 50,000 FCH/4 or 10,000 FVO parasites. Three of the six animals in the AMA+ISA group were protected against FCH/4 challenge. One monkey did not become parasitemic, another showed only a short period of low level parasitemia that self-cured, and a third animal showed a delay before exhibiting its parasitemic phase. This is the first protection shown in primates with a recombinant P. falciparum AMA1 without formulation in Freund's complete adjuvant. No animals in the AMA+AS02(A) group were protected, but this group exhibited a trend towards reduced growth rate. A second group of monkeys vaccinated with AMA+ISA vaccine was not protected against FVO challenge, suggesting strain-specificity of AMA1-based protection. Protection against FCH/4 strain correlated with the quantity of induced antibodies, as the protected animals were the only ones to have in vitro parasite growth inhibitory activity of >70% at 1:10 serum dilution; immuno-fluorescence titers >8,000; ELISA titers against full-length AMA1 >300,000 and ELISA titer against AMA1 domains1+2 >100,000. A negative correlation between log ELISA titer and day 11 cumulative parasitemia (Spearman rank r = -0.780, p value = 0.0001), further confirmed the relationship between antibody titer and protection. High titers of cross-strain inhibitory antibodies against AMA1 are therefore critical to confer solid protection, and the Aotus model can be used to down-select future AMA1 formulations, prior to advanced human trials.
Malaria vaccines: a new era of prevention and control.
Duffy P, Gorres J, Healy S, Fried M Nat Rev Microbiol. 2024; 22(12):756-772.
PMID: 39025972 DOI: 10.1038/s41579-024-01065-7.
Yanik S, Venkatesh V, Parker M, Ramaswamy R, Diouf A, Sarkar D Nat Commun. 2023; 14(1):5879.
PMID: 37735574 PMC: 10514071. DOI: 10.1038/s41467-023-41636-5.
Structure-based design of a strain transcending AMA1-RON2L malaria vaccine.
Patel P, Dickey T, Diouf A, Salinas N, McAleese H, Ouahes T Nat Commun. 2023; 14(1):5345.
PMID: 37660103 PMC: 10475129. DOI: 10.1038/s41467-023-40878-7.
Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies.
Miura K, Diouf A, Fay M, Barrett J, Payne R, Olotu A Malar J. 2023; 22(1):159.
PMID: 37208733 PMC: 10196285. DOI: 10.1186/s12936-023-04591-6.
Srinivasan P, Yanik S, Venkatesh V, Parker M, Diouf A, Sarkar D Res Sq. 2023; .
PMID: 37131813 PMC: 10153359. DOI: 10.21203/rs.3.rs-2733434/v1.